Author:
Alakeel Yousif S.,Alahmed Yazeed,Alanazi Ghadah,Alawbathani Bushra,Alshutwi Kadi,Almeshary Meshary,Aldhahri Fahad,Alshakrah Meshal
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [published correction appears in Clin Infect Dis. 2011;53(3):319]. Clin Infect Dis. 2011;52(3):e18-e55. https://doi.org/10.1093/cid/ciq146
2. Thomas CA, Picone A, Menon S, Willis BC. Empirical vancomycin dosing in Pediatric patients with congenital heart Disease and the impact of cardiopulmonary bypass on trough concentrations. Pharmacotherapy. 2017;37(11):1341–6. https://doi.org/10.1002/phar.2019.
3. Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of Vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the society of infectious diseases pharmacists. Clin Biochem Rev. 2010;31(1):21–4.
4. Hoang J, Dersch-Mills D, Bresee L, Kraft T, Vanderkooi OG. Achieving therapeutic Vancomycin levels in pediatric patients. Can J Hosp Pharm. 2014;67(6):416–22. https://doi.org/10.4212/cjhp.v67i6.1403.
5. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of Vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28(5):398–402. https://doi.org/10.1097/INF.0b013e3181906e40.